Dr Reddy's Q2 Profit Falls 36%, Shares Rise on Margin Recovery and Product Outlook
Dr Reddy's Laboratories reported a 36% year-on-year decline in Q2FY27 net profit to Rs 925 crore, with a slight revenue drop due to lower North American lenalidomide sales. Despite this, shares rose on expectations of margin recovery and upcoming product launches like semaglutide and abatacept. Brokerages offered mixed ratings: Nomura retained 'Buy' but lowered its target, Citi raised its target and maintained 'Buy', Jefferies upgraded to 'Hold', while Goldman Sachs and Kotak Neo remained cautious. Prabhudas Lilladher maintained an 'Accumulate' rating, highlighting strong domestic and Russia sales and pipeline investments.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 39/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Oct, 05:20 am. Other outlets followed.